The dose of HALDOL Decanoate 50 or HALDOL Decanoate 100 should be expressed in terms of its haloperidol content. The starting dose of haloperidol decanoate should be based on the patient's age, clinical history, physical condition, and response to previous antipsychotic therapy. The preferred approach to determining the minimum effective dose is to begin with lower initial doses and to adjust the dose upward as needed. For patients previously maintained on low doses of antipsychotics (. up to the equivalent of 10 mg/day oral haloperidol), it is recommended that the initial dose of haloperidol decanoate be 10–15 times the previous daily dose in oral haloperidol equivalents; limited clinical experience suggests that lower initial doses may be adequate.
Manus Aktteva Biopharma LLP, an ISO 9001: 2008 certified sourcing & export concern takes pride in fulfilling your requirements of Nutraceuticals, Specialty Chemicals, Pharmaceutical APIs and their advance level intermediates from ISO Certified, GMP, CGMP & USFDA approved units with supportive regulatory documentations like DMF, EDMF, COS, USDMF etc. We wish to state that anyone interested in sourcing any special molecules, APIs, Intermediates, Chiral Compounds etc. and feels it is difficult for early completion of tasks, please call on us and TEST US TO GET THE BEST OF US.
2 to 5 mg IM single dose initially; use if oral therapy is not appropriate; may administer as frequently as 1 hour intervals, though dosing every 4 to 8 hours is satisfactory for most patients. Max: 20 mg/day IM. Repeat doses based on clinical response and safety considerations. Geriatric patients may require a lower dose; use lower starting dose and titrate gradually. Use the lowest effective dose in all patients. Convert to oral therapy as soon as clinically indicated. Second generation antipsychotics with efficacy for this indication (oral or parenteral, ., risperidone, olanzapine, or ziprasidone), may be preferred due to cardiac and extrapyramidal risks of parenteral haloperidol. In some patients, the addition of a benzodiazepine may be needed. SWITCHING TO ORAL THERAPY: In general, the parenteral dose administered in the preceding 24 hours may be used as the total initial daily PO dosage. Thereafter, closely monitor and adjust oral dosage to efficacy and tolerance. Usually, the first oral dose should be given within 12 to 24 hours following the last IM dose.